Get the Stockscreener App
3.20
1.27%
0.04
Organogenesis Holdings Inc stock is traded at $3.20, with a volume of 521.11K.
It is up +1.27% in the last 24 hours and down -17.31% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
See More
Previous Close:
$3.16
Open:
$3.18
24h Volume:
521.11K
Relative Volume:
0.79
Market Cap:
$424.24M
Revenue:
$433.14M
Net Income/Loss:
$4.95M
P/E Ratio:
39.22
EPS:
0.0816
Net Cash Flow:
$6.55M
1W Performance:
+0.63%
1M Performance:
-17.31%
6M Performance:
+14.29%
1Y Performance:
-21.76%
1-Day Range:
$3.12
$3.265
1-Week Range:
$3.10
$3.39
52-Week Range:
$2.165
$4.705
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
3.20 | 424.24M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
ZTS
Zoetis Inc
|
162.93 | 73.51B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.54 | 43.13B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.24 | 41.98B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.04 | 24.97B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.45 | 14.86B | 15.05B | -883.30M | 1.89B | -0.74 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Bought by State Street Corp - Defense World
Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Up 29.1% in December - MarketBeat
Organogenesis signs Smithfield lease with subsidies in hand - The Business Journals
Fmr LLC Buys 44,199 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) - Defense World
Gary S. Gillheeney Sells 5,585 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock - MarketBeat
Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 55,615 Shares - MarketBeat
Organogenesis CEO Gary Gillheeney sells shares worth $206,358 - Investing.com
US Penny Stocks To Consider In December 2024 - Simply Wall St
Charles Schwab Investment Management Inc. Grows Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO) - Defense World
Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Bought by Verition Fund Management LLC - Defense World
Organogenesis Holdings Inc. (NASDAQ:ORGO) Position Cut by BNP Paribas Financial Markets - Defense World
Organogenesis CEO Gary Gillheeney sells shares worth $940,066 - Investing.com
Organogenesis CEO Gary Gillheeney sells shares worth $940,066 By Investing.com - Investing.com UK
Wound Care Market 2024By Industry Outlook, Future Trends, - openPR
Organogenesis CEO Gillheeney sells shares worth $211,721 - Investing.com India
Organogenesis CEO Gillheeney sells shares worth $211,721 By Investing.com - Investing.com Nigeria
Jacobs Levy Equity Management Inc. Lowers Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO) - MarketBeat
Organogenesis Holdings Inc (NASDAQ: ORGO) -0.26% Decline Turns Investors Away - Stocks Register
Organogenesis Holdings Inc. announces an Equity Buyback for 500,000 shares, for $2.03 million. - Marketscreener.com
Organogenesis announces stock repurchase at trailing average price By Investing.com - Investing.com Australia
Organogenesis announces stock repurchase at trailing average price - Investing.com
Advantage Alpha Capital Partners LP Trims Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) - MarketBeat
News | Massachusetts-based regenerative tissue medical firm expands in Rhode Island - CoStar Group
News | Massachusetts-based regenerative medical firm expands in Rhode Island - CoStar Group
Organogenesis Expands Manufacturing Capacity to Support Future Growth - The Manila Times
Organogenesis Holdings Inc. Expands Manufacturing Capacity to Support Future Growth - Marketscreener.com
Organogenesis Secures 122,000 Sq Ft Biomanufacturing Facility in Major Expansion | ORGO Stock News - StockTitan
Organogenesis Holdings Inc. Appoints Garrett Lustig to the Board - Marketscreener.com
Analysts Set Expectations for Organogenesis FY2024 Earnings - Defense World
Organogenesis Holdings’ $130 Million Private Placement Offering of Series A Convertible Preferred Stock - Global Legal Chronicle
FY2024 EPS Estimates for Organogenesis Boosted by Analyst - MarketBeat
Organogenesis (NASDAQ:ORGO) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Organogenesis Commends Final LCDs - The Manila Times
Organogenesis Secures Medicare Coverage for Wound Care Products in Key CMS Decision | ORGO Stock News - StockTitan
Organogenesis (NASDAQ:ORGO) Shares Gap DownWhat's Next? - MarketBeat
Earnings call: Organogenesis tops Q3 revenue forecast with $115.2M - Investing.com
Organogenesis Holdings Secures $130M Investment for Growth - TipRanks
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q3 2024 Earnings Call Transcript - Insider Monkey
Organogenesis secures $130 million investment By Investing.com - Investing.com Australia
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results - The Manila Times
Organogenesis: Q3 Earnings Snapshot - The Washington Post
Organogenesis Reports Robust Third Quarter Growth - TipRanks
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript - The Motley Fool
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates - Yahoo Canada Finance
Organogenesis Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock - The Manila Times
Organogenesis Secures $130M Investment from Avista, Strengthens Growth Strategy | ORGO Stock News - StockTitan
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organogenesis Holdings Inc Stock (ORGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gillheeney Gary S. | President and CEO |
Dec 16 '24 |
Sale |
3.49 |
5,585 |
19,492 |
3,039,194 |
| Gillheeney Gary S. | President and CEO |
Dec 11 '24 |
Sale |
3.64 |
157,448 |
573,111 |
3,143,753 |
| Gillheeney Gary S. | President and CEO |
Dec 10 '24 |
Sale |
3.64 |
58,525 |
213,031 |
3,301,201 |
| Gillheeney Gary S. | President and CEO |
Dec 12 '24 |
Sale |
3.55 |
43,359 |
153,924 |
3,100,394 |
| Gillheeney Gary S. | President and CEO |
Dec 05 '24 |
Option Exercise |
0.99 |
1,067,245 |
1,056,573 |
3,419,194 |
| Gillheeney Gary S. | President and CEO |
Dec 09 '24 |
Sale |
3.52 |
41,052 |
144,503 |
3,359,726 |
| Gillheeney Gary S. | President and CEO |
Dec 06 '24 |
Sale |
3.65 |
18,416 |
67,218 |
3,400,778 |
2.45%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):